Your browser is no longer supported

For the best possible experience using our website we recommend you upgrade to a newer version or another browser.

Your browser appears to have cookies disabled. For the best experience of this website, please enable cookies in your browser

We'll assume we have your consent to use cookies, for example so you won't need to log in each time you visit our site.
Learn more

Glass risk sparks alert of asthma treatment

  • Comment

A drug alert has been issued over the risk of glass particles in some batches of an asthma treatment.

A class 2 drug alert was issued yesterday advising of the recall of two batches of Ventolin Syrup sugar-free 2mg in 5ml supplied  by Glaxo Wellcome UK Ltd, trading as Allen & Hanburys. 

The Medicines and Healthcare products Regulatory Agency said there was a very low risk of glass particles being contained in 1,375 bottles of the asthma treatment dispensed to pharmacies from batches numbered M005 and M006.

MHRA gead of defective medicines report centre Adam Burgess said: “There is a very low risk of glass particles being contained in bottles of Ventolin Syrup but patients who have been prescribed this product should check the batch numbers.”

  • Comment

Have your say

You must sign in to make a comment

Please remember that the submission of any material is governed by our Terms and Conditions and by submitting material you confirm your agreement to these Terms and Conditions. Links may be included in your comments but HTML is not permitted.